

AMOXICILLIN- amoxicillin capsule
AMOXICILLIN- amoxicillin powder, for suspension
AMOXICILLIN- amoxicillin tablet, chewable
Teva Pharmaceuticals USA, Inc.

HIGHLIGHTS OF PRESCRIBING INFORMATION

These highlights do not include all the information needed to use AMOXICILLIN CAPSULES, AMOXICILLIN FOR ORAL SUSPENSION, and AMOXICILLIN TABLETS (CHEWABLE) safely and effectively. See full prescribing information for AMOXICILLIN CAPSULES, AMOXICILLIN FOR ORAL SUSPENSION, and AMOXICILLIN TABLETS (CHEWABLE).

AMOXICILLIN capsules, AMOXICILLIN for oral suspension, and AMOXICILLIN tablets (chewable) for oral use

Initial U.S. Approval: 1974

----- **INDICATIONS AND USAGE** -----

Amoxicillin is a penicillin-class antibacterial indicated for treatment of infections due to susceptible strains of designated microorganisms.

- Infections of the ear, nose, throat, genitourinary tract, skin and skin structure, and lower respiratory tract. (1.1 to 1.4)
- In combination for treatment of *H. pylori* infection and duodenal ulcer disease. (1.5)

To reduce the development of drug-resistant bacteria and maintain the effectiveness of amoxicillin capsules, amoxicillin for oral suspension, amoxicillin tablets (chewable) and other antibacterial drugs, amoxicillin capsules, amoxicillin for oral suspension, and amoxicillin tablets (chewable) should be used only to treat infections that are proven or strongly suspected to be caused by bacteria. (1.6)

----- **DOSAGE AND ADMINISTRATION** -----

- In adults, 750 to 1750 mg/day in divided doses every 8 to 12 hours. In Pediatric Patients > 3 Months of Age, 20 to 45 mg/kg/day in divided doses every 8 to 12 hours. Refer to full prescribing information for specific dosing regimens. (2.1, 2.2, 2.3)
- The upper dose for neonates and infants ≤ 3 months is 30 mg/kg/day divided every 12 hours. (2.2)
- Dosing for *H. pylori* Infection: Triple therapy: 1 gram amoxicillin, 500 mg clarithromycin, and 30 mg lansoprazole, all given twice daily (every 12 hours) for 14 days. Dual therapy: 1 gram amoxicillin and 30 mg lansoprazole, each given three times daily (every 8 hours) for 14 days. (2.3)
- Reduce the dose in patients with severe renal impairment (GFR < 30 mL/min). (2.4)

----- **DOSAGE FORMS AND STRENGTHS** -----

- Capsules: 250 mg, 500 mg (3)
- Powder for Oral Suspension: 125 mg/5 mL, 250 mg/5 mL (3)
- Tablets (Chewable): 125 mg, 250 mg (3)

----- **CONTRAINDICATIONS** -----

- History of a serious hypersensitivity reaction (e.g., anaphylaxis or Stevens-Johnson syndrome) to amoxicillin or to other beta-lactams (e.g., penicillins or cephalosporins) (4)

----- **WARNINGS AND PRECAUTIONS** -----

- Anaphylactic Reactions: Serious and occasionally fatal anaphylactic reactions have been reported in patients on penicillin therapy. Serious anaphylactic reactions require immediate emergency treatment with supportive measures. (5.1)
- *Clostridium difficile* Associated Diarrhea (ranging from mild diarrhea to fatal colitis): Evaluate if diarrhea occurs. (5.2)

----- **ADVERSE REACTIONS** -----

The most common adverse reactions (> 1%) observed in clinical trials of amoxicillin capsules, tablets (chewable) or oral suspension were diarrhea, rash, vomiting, and nausea. (6.1)

To report SUSPECTED ADVERSE REACTIONS, contact Teva Pharmaceuticals USA, Inc. at 1-888-838-2872 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

----- **DRUG INTERACTIONS** -----

- Probenicid decreases renal tubular secretion of amoxicillin which may result in increased blood levels of amoxicillin. (7.1)
- Concomitant use of amoxicillin and oral anticoagulants may increase the prolongation of prothrombin time. (7.2)

- Coadministration with allopurinol increases the risk of rash. (7.3)
- Amoxicillin may reduce the efficacy of oral contraceptives. (7.4)

----- **USE IN SPECIFIC POPULATIONS** -----

- Pediatric: Modify dose in patients 12 weeks or younger (≤ 3 months). (8.4)

See 17 for PATIENT COUNSELING INFORMATION.

Revised: 8/2018

FULL PRESCRIBING INFORMATION: CONTENTS*

1 INDICATIONS AND USAGE

- 1.1 Infections of the Ear, Nose, and Throat
- 1.2 Infections of the Genitourinary Tract
- 1.3 Infections of the Skin and Skin Structure
- 1.4 Infections of the Lower Respiratory Tract
- 1.5 *Helicobacter pylori* Infection
- 1.6 Usage

2 DOSAGE AND ADMINISTRATION

- 2.1 Dosing for Adult and Pediatric Patients > 3 Months of Age
- 2.2 Dosing in Neonates and Infants Aged ≤ 12 Weeks (≤ 3 Months)
- 2.3 Dosing for *H. pylori* Infection
- 2.4 Dosing in Renal Impairment
- 2.5 Directions for Mixing Oral Suspension

3 DOSAGE FORMS AND STRENGTHS

4 CONTRAINDICATIONS

5 WARNINGS AND PRECAUTIONS

- 5.1 Anaphylactic Reactions
- 5.2 *Clostridium difficile* Associated Diarrhea
- 5.3 Development of Drug-Resistant Bacteria
- 5.4 Use in Patients With Mononucleosis

6 ADVERSE REACTIONS

- 6.1 Clinical Trials Experience
- 6.2 Postmarketing or Other Experience

7 DRUG INTERACTIONS

- 7.1 Probenecid
- 7.2 Oral Anticoagulants
- 7.3 Allopurinol
- 7.4 Oral Contraceptives
- 7.5 Other Antibacterials
- 7.6 Effects on Laboratory Tests

8 USE IN SPECIFIC POPULATIONS

- 8.1 Pregnancy
- 8.2 Labor and Delivery
- 8.3 Nursing Mothers
- 8.4 Pediatric Use
- 8.5 Geriatric Use
- 8.6 Dosing in Renal Impairment

10 OVERDOSAGE

11 DESCRIPTION

12 CLINICAL PHARMACOLOGY

- 12.1 Mechanism of Action

12.3 Pharmacokinetics

12.4 Microbiology

13 NONCLINICAL TOXICOLOGY

13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

14 CLINICAL STUDIES

14.1 *H. pylori* Eradication to Reduce the Risk of Duodenal Ulcer Recurrence

15 REFERENCES

16 HOW SUPPLIED/STORAGE AND HANDLING

17 PATIENT COUNSELING INFORMATION

Amoxicillin Capsules USP 250 mg 500s Label Text

Amoxicillin Capsules USP 500 mg 500s Label Text

Amoxicillin for Oral Suspension USP 125 mg per 5 mL 100 mL Label Text

Amoxicillin for Oral Suspension USP 250 mg per 5 mL 100 mL Label Text

Amoxicillin Tablets USP (Chewable) 125 mg 100s Label Text

Amoxicillin Tablets USP (Chewable) 250 mg 500s Label Text

* Sections or subsections omitted from the full prescribing information are not listed.

FULL PRESCRIBING INFORMATION

1 INDICATIONS AND USAGE

1.1 Infections of the Ear, Nose, and Throat

Amoxicillin capsules, amoxicillin for oral suspension, amoxicillin tablets (chewable) are indicated in the treatment of infections due to susceptible (ONLY β -lactamase–negative) isolates of *Streptococcus* species (α - and β -hemolytic isolates only), *Streptococcus pneumoniae*, *Staphylococcus* spp., or *Haemophilus influenzae*.

1.2 Infections of the Genitourinary Tract

Amoxicillin capsules, amoxicillin for oral suspension, amoxicillin tablets (chewable) are indicated in the treatment of infections due to susceptible (ONLY β -lactamase–negative) isolates of *Escherichia coli*, *Proteus mirabilis*, or *Enterococcus faecalis*.

1.3 Infections of the Skin and Skin Structure

Amoxicillin capsules, amoxicillin for oral suspension, amoxicillin tablets (chewable) are indicated in the treatment of infections due to susceptible (ONLY β -lactamase-negative) isolates of *Streptococcus* spp. (α - and β -hemolytic isolates only), *Staphylococcus* spp., or *E. coli*.

1.4 Infections of the Lower Respiratory Tract

Amoxicillin capsules, amoxicillin for oral suspension, amoxicillin tablets (chewable) are indicated in the treatment of infections due to susceptible (ONLY β -lactamase-negative) isolates of *Streptococcus* spp. (α - and β -hemolytic isolates only), *S. pneumoniae*, *Staphylococcus* spp., or *H. influenzae*.

1.5 *Helicobacter pylori* Infection

Triple therapy for *Helicobacter pylori* with clarithromycin and lansoprazole:

Amoxicillin, in combination with clarithromycin plus lansoprazole as triple therapy, is indicated for the treatment of patients with *H. pylori* infection and duodenal ulcer disease (active or 1 year history of a duodenal ulcer) to eradicate *H. pylori*. Eradication of *H. pylori* has been shown to reduce the risk of duodenal ulcer recurrence.

Dual therapy for *H. pylori* with lansoprazole:

Amoxicillin, in combination with lansoprazole delayed-release capsules as dual therapy, is indicated for the treatment of patients with *H. pylori* infection and duodenal ulcer disease (active or 1 year history of a duodenal ulcer) **who are either allergic or intolerant to clarithromycin or in whom resistance to clarithromycin is known or suspected.** (See the clarithromycin package insert, MICROBIOLOGY.) Eradication of *H. pylori* has been shown to reduce the risk of duodenal ulcer recurrence.

1.6 Usage

To reduce the development of drug-resistant bacteria and maintain the effectiveness of amoxicillin and other antibacterial drugs, amoxicillin should be used only to treat infections that are proven or strongly suspected to be caused by bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.

2 DOSAGE AND ADMINISTRATION

2.1 Dosing for Adult and Pediatric Patients > 3 Months of Age

Treatment should be continued for a minimum of 48 to 72 hours beyond the time that the patient becomes asymptomatic or evidence of bacterial eradication has been obtained. It is recommended that there be at least 10 days' treatment for any infection caused by *Streptococcus pyogenes* to prevent the occurrence of acute rheumatic fever. In some infections, therapy may be required for several weeks. It may be necessary to continue clinical and/or bacteriological follow-up for several months after cessation of therapy.

Table 1. Dosing Recommendations for Adult and Pediatric Patients > 3 Months of Age

Infection	Severity ^a	Usual Adult Dose	Usual Dose for Children > 3 Months ^b
Ear/Nose/Throat Skin/Skin Structure Genitourinary Tract	Mild/Moderate	500 mg every 12 hours or 250 mg every 8 hours	25 mg/kg/day in divided doses every 12 hours or 20 mg/kg/day in divided doses every 8 hours
	Severe	875 mg every 12 hours or 500 mg every 8 hours	45 mg/kg/day in divided doses every 12 hours or 40 mg/kg/day in divided doses every 8 hours
Lower Respiratory Tract	Mild/Moderate or Severe	875 mg every 12 hours or 500 mg every 8 hours	45 mg/kg/day in divided doses every 12 hours or 40 mg/kg/day in divided doses every 8 hours

^a. Dosing for infections caused by bacteria that are intermediate in their susceptibility to amoxicillin should follow the recommendations for severe infections.

^b. The children's dosage is intended for individuals whose weight is less than 40 kg. Children weighing 40 kg or more should be dosed according to the adult recommendations.

2.2 Dosing in Neonates and Infants Aged ≤ 12 Weeks (≤ 3 Months)

Treatment should be continued for a minimum of 48 to 72 hours beyond the time that the patient becomes asymptomatic or evidence of bacterial eradication has been obtained. It is recommended that there be at least 10 days' treatment for any infection caused by *Streptococcus pyogenes* to prevent the occurrence of acute rheumatic fever. Due to incompletely developed renal function affecting elimination of amoxicillin in this age group, the recommended upper dose of amoxicillin is 30 mg/kg/day divided every 12 hours. There are currently no dosing recommendations for pediatric patients with impaired renal function.

2.3 Dosing for *H. pylori* Infection

Triple Therapy: The recommended adult oral dose is 1 gram amoxicillin, 500 mg clarithromycin, and 30 mg lansoprazole, all given twice daily (every 12 hours) for 14 days.

Dual Therapy: The recommended adult oral dose is 1 gram amoxicillin and 30 mg lansoprazole, each given three times daily (every 8 hours) for 14 days.

Please refer to clarithromycin and lansoprazole full prescribing information.

2.4 Dosing in Renal Impairment

- Patients with impaired renal function do not generally require a reduction in dose unless the impairment is severe.
- Severely impaired patients with a glomerular filtration rate of < 30 mL/min should not receive a 875 mg dose.
- Patients with a glomerular filtration rate of 10 to 30 mL/min should receive 500 mg or 250 mg every 12 hours, depending on the severity of the infection.
- Patients with a glomerular filtration rate less than 10 mL/min should receive 500 mg or 250 mg every 24 hours, depending on severity of the infection.
- Hemodialysis patients should receive 500 mg or 250 mg every 24 hours, depending on severity of the infection. They should receive an additional dose both during and at the end of dialysis.

2.5 Directions for Mixing Oral Suspension

Tap bottle until all powder flows freely. Add approximately 1/3 of the total amount of water for reconstitution (see Table 2) and shake vigorously to wet powder. Add remainder of the water and again shake vigorously.

Table 2. Amount of Water for Mixing Oral Suspension

Strength	<u>Bottle Size</u>	<u>Amount of Water Required for Reconstitution</u>
Oral Suspension 125 mg/5 mL	80 mL	62 mL
	100 mL	77 mL
	150 mL	113 mL
Oral Suspension 250 mg/5 mL	80 mL	47 mL
	100 mL	60 mL
	150 mL	90 mL

After reconstitution, the required amount of suspension should be placed directly on the child's tongue for swallowing. Alternate means of administration are to add the required amount of suspension to formula, milk, fruit juice, water, ginger ale, or cold drinks. These preparations should then be taken immediately.

NOTE: SHAKE ORAL SUSPENSION WELL BEFORE USING. Keep bottle tightly closed. Any unused portion of the reconstituted suspension must be discarded after 14 days. Refrigeration is preferable, but not required.

3 DOSAGE FORMS AND STRENGTHS

Amoxicillin Capsules USP

250 mg: Opaque caramel cap and opaque buff body, hard gelatin capsule. Printed black “TEVA” on cap and “3107” on body portions of the capsule and contain 250 mg amoxicillin as the trihydrate.

500 mg: Opaque buff cap and opaque buff body, hard gelatin capsules. Printed black “TEVA” on cap and “3109” on body portions of the capsules and contain 500 mg amoxicillin as the trihydrate.

Amoxicillin for Oral Suspension USP

125 mg/5 mL: Each 5 mL of reconstituted mixed berry flavored suspension contains 125 mg amoxicillin as the trihydrate.

250 mg/5 mL: Each 5 mL of reconstituted mixed berry flavored suspension contains 250 mg amoxicillin as the trihydrate.

Amoxicillin Tablets USP (Chewable)

125 mg: White to off-white, capsule-shaped tablet, unscored, debossed 93 on one side and 2267 on the other side and contain 125 mg amoxicillin as the trihydrate.

250 mg: White to off-white, capsule-shaped tablet, debossed 93 (partial bisect between 9 and 3) on one side and 2268 on the other side and contain 250 mg amoxicillin as the trihydrate.

4 CONTRAINDICATIONS

Amoxicillin is contraindicated in patients who have experienced a serious hypersensitivity reaction (e.g., anaphylaxis or Stevens-Johnson syndrome) to amoxicillin or to other β -lactam antibiotics (e.g., penicillins and cephalosporins).

5 WARNINGS AND PRECAUTIONS

5.1 Anaphylactic Reactions

Serious and occasionally fatal hypersensitivity (anaphylactic) reactions have been reported in patients on penicillin therapy including amoxicillin. Although anaphylaxis is more frequent following parenteral therapy, it has occurred in patients on oral penicillins. These reactions are more likely to occur in individuals with a history of penicillin hypersensitivity and/or a history of sensitivity to multiple allergens. There have been reports of individuals with a history of penicillin hypersensitivity who have experienced severe reactions when treated with cephalosporins. Before initiating therapy with amoxicillin, careful inquiry should be made regarding previous hypersensitivity reactions to penicillins, cephalosporins, or other allergens. If an allergic reaction occurs, amoxicillin should be discontinued and appropriate therapy instituted.

5.2 *Clostridium difficile* Associated Diarrhea

Clostridium difficile associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents, including amoxicillin, and may range in severity from mild diarrhea to fatal colitis. Treatment with antibacterial agents alters the normal flora of the colon leading to overgrowth of *C. difficile*.

C. difficile produces toxins A and B which contribute to the development of CDAD. Hypertoxin-producing strains of *C. difficile* cause increased morbidity and mortality, as these infections can be refractory to antimicrobial therapy and may require colectomy. CDAD must be considered in all patients who present with diarrhea following antibacterial use. Careful medical history is necessary since CDAD has been reported to occur over 2 months after the administration of antibacterial agents.

If CDAD is suspected or confirmed, ongoing antibiotic use not directed against *C. difficile* may need to

be discontinued. Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of *C. difficile*, and surgical evaluation should be instituted as clinically indicated.

5.3 Development of Drug-Resistant Bacteria

Prescribing amoxicillin in the absence of a proven or strongly suspected bacterial infection is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria.

5.4 Use in Patients With Mononucleosis

A high percentage of patients with mononucleosis who receive amoxicillin develop an erythematous skin rash. Thus amoxicillin should not be administered to patients with mononucleosis.

6 ADVERSE REACTIONS

The following are discussed in more detail in other sections of the labeling:

- Anaphylactic reactions [see *Warnings and Precautions (5.1)*]
- CDAD [see *Warnings and Precautions (5.2)*]

6.1 Clinical Trials Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

The most common adverse reactions (> 1%) observed in clinical trials of amoxicillin capsules, tablets or oral suspension were diarrhea, rash, vomiting, and nausea.

Triple Therapy: The most frequently reported adverse events for patients who received triple therapy (amoxicillin/clarithromycin/lansoprazole) were diarrhea (7%), headache (6%), and taste perversion (5%).

Dual Therapy: The most frequently reported adverse events for patients who received double therapy amoxicillin/lansoprazole were diarrhea (8%) and headache (7%). For more information on adverse reactions with clarithromycin or lansoprazole, refer to the Adverse Reactions section of their package inserts.

6.2 Postmarketing or Other Experience

In addition to adverse events reported from clinical trials, the following events have been identified during postmarketing use of penicillins. Because they are reported voluntarily from a population of unknown size, estimates of frequency cannot be made. These events have been chosen for inclusion due to a combination of their seriousness, frequency of reporting, or potential causal connection to amoxicillin.

- **Infections and Infestations:** Mucocutaneous candidiasis.
- **Gastrointestinal:** Black hairy tongue and hemorrhagic/pseudomembranous colitis. Onset of pseudomembranous colitis symptoms may occur during or after antibacterial treatment [see *Warnings and Precautions (5.2)*].
- **Hypersensitivity Reactions:** Anaphylaxis [see *Warnings and Precautions (5.1)*]. Serum sickness–like reactions, erythematous maculopapular rashes, erythema multiforme, Stevens-Johnson syndrome, exfoliative dermatitis, toxic epidermal necrolysis, acute generalized exanthematous pustulosis, hypersensitivity vasculitis, and urticaria have been reported.
- **Liver:** A moderate rise in AST and/or ALT has been noted, but the significance of this finding is unknown. Hepatic dysfunction including cholestatic jaundice, hepatic cholestasis and acute cytolytic hepatitis have been reported.
- **Renal:** Crystalluria has been reported [see *Overdosage (10)*].
- **Hemic and Lymphatic Systems:** Anemia, including hemolytic anemia, thrombocytopenia,

thrombocytopenic purpura, eosinophilia, leukopenia, and agranulocytosis have been reported. These reactions are usually reversible on discontinuation of therapy and are believed to be hypersensitivity phenomena.

- **Central Nervous System:** Reversible hyperactivity, agitation, anxiety, insomnia, confusion, convulsions, behavioral changes, and/or dizziness have been reported.
- **Miscellaneous:** Tooth discoloration (brown, yellow, or gray staining) has been reported. Most reports occurred in pediatric patients. Discoloration was reduced or eliminated with brushing or dental cleaning in most cases.

7 DRUG INTERACTIONS

7.1 Probenecid

Probenecid decreases the renal tubular secretion of amoxicillin. Concurrent use of amoxicillin and probenecid may result in increased and prolonged blood levels of amoxicillin.

7.2 Oral Anticoagulants

Abnormal prolongation of prothrombin time (increased international normalized ratio [INR]) has been reported in patients receiving amoxicillin and oral anticoagulants. Appropriate monitoring should be undertaken when anticoagulants are prescribed concurrently. Adjustments in the dose of oral anticoagulants may be necessary to maintain the desired level of anticoagulation.

7.3 Allopurinol

The concurrent administration of allopurinol and amoxicillin increases the incidence of rashes in patients receiving both drugs as compared to patients receiving amoxicillin alone. It is not known whether this potentiation of amoxicillin rashes is due to allopurinol or the hyperuricemia present in these patients.

7.4 Oral Contraceptives

Amoxicillin may affect the gut flora, leading to lower estrogen reabsorption and reduced efficacy of combined oral estrogen/progesterone contraceptives.

7.5 Other Antibacterials

Chloramphenicol, macrolides, sulfonamides, and tetracyclines may interfere with the bactericidal effects of penicillin. This has been demonstrated *in vitro*; however, the clinical significance of this interaction is not well documented.

7.6 Effects on Laboratory Tests

High urine concentrations of ampicillin may result in false-positive reactions when testing for the presence of glucose in urine using CLINITEST[®], Benedict's Solution, or Fehling's Solution. Since this effect may also occur with amoxicillin, it is recommended that glucose tests based on enzymatic glucose oxidase reactions (such as CLINISTIX[®]) be used.

Following administration of ampicillin or amoxicillin to pregnant women, a transient decrease in plasma concentration of total conjugated estriol, estriol-glucuronide, conjugated estrone, and estradiol has been noted.

8 USE IN SPECIFIC POPULATIONS

8.1 Pregnancy

Teratogenic Effects

Pregnancy Category B

Reproduction studies have been performed in mice and rats at doses up to 2000 mg/kg (3 and 6 times the 3 g human dose, based on body surface area). There was no evidence of harm to the fetus due to amoxicillin. There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, amoxicillin should be used during pregnancy only if clearly needed.

8.2 Labor and Delivery

Oral ampicillin is poorly absorbed during labor. It is not known whether use of amoxicillin in humans during labor or delivery has immediate or delayed adverse effects on the fetus, prolongs the duration of labor, or increases the likelihood of the necessity for an obstetrical intervention.

8.3 Nursing Mothers

Penicillins have been shown to be excreted in human milk. Amoxicillin use by nursing mothers may lead to sensitization of infants. Caution should be exercised when amoxicillin is administered to a nursing woman.

8.4 Pediatric Use

Because of incompletely developed renal function in neonates and young infants, the elimination of amoxicillin may be delayed. Dosing of amoxicillin should be modified in pediatric patients 12 weeks or younger (≤ 3 months) [*see Dosage and Administration (2.2)*].

8.5 Geriatric Use

An analysis of clinical studies of amoxicillin was conducted to determine whether subjects aged 65 and over respond differently from younger subjects. These analyses have not identified differences in responses between the elderly and younger patients, but a greater sensitivity of some older individuals cannot be ruled out.

This drug is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function.

8.6 Dosing in Renal Impairment

Amoxicillin is primarily eliminated by the kidney and dosage adjustment is usually required in patients with severe renal impairment ($\text{GFR} < 30 \text{ mL/min}$). See Dosing in Renal Impairment (2.4) for specific recommendations in patients with renal impairment.

10 OVERDOSAGE

In case of overdosage, discontinue medication, treat symptomatically, and institute supportive measures as required. A prospective study of 51 pediatric patients at a poison-control center suggested that overdosages of less than 250 mg/kg of amoxicillin are not associated with significant clinical symptoms.

Interstitial nephritis resulting in oliguric renal failure has been reported in a small number of patients after overdosage with amoxicillin¹.


Crystalluria, in some cases leading to renal failure, has also been reported after amoxicillin overdosage in adult and pediatric patients. In case of overdosage, adequate fluid intake and diuresis should be maintained to reduce the risk of amoxicillin crystalluria.

Renal impairment appears to be reversible with cessation of drug administration. High blood levels may

occur more readily in patients with impaired renal function because of decreased renal clearance of amoxicillin. Amoxicillin may be removed from circulation by hemodialysis.

11 DESCRIPTION

Amoxicillin, USP is a semisynthetic antibiotic, an analog of ampicillin, with a broad spectrum of bactericidal activity against many gram-positive and gram-negative microorganisms. Chemically, it is (2*S*,5*R*,6*R*)-6-[(*R*)-(-)-2-amino-2-(*p*-hydroxyphenyl)acetamido]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid trihydrate. The structural formula is:



$\text{C}_{16}\text{H}_{19}\text{N}_3\text{O}_5\text{S}\cdot 3\text{H}_2\text{O}$ M.W. 419.45

Amoxicillin Capsules USP

Each capsule, for oral administration, contains 250 mg or 500 mg amoxicillin, USP as the trihydrate.

Inactive Ingredients: CAPSULES-DRUG PRODUCT: magnesium stearate, talc.

CAPSULE SHELL AND PRINT CONSTITUENTS: black iron oxide, D&C Yellow #10, D&C Yellow #10 Aluminum Lake, FD&C Blue #1 Aluminum Lake, FD&C Blue #2 Aluminum Lake, FD&C Red #40, FD&C Red #40 Aluminum Lake, gelatin, propylene glycol, shellac, titanium dioxide. In addition, the 500 mg capsule shell may also contain methylparaben, potassium hydroxide, propylparaben, and sodium lauryl sulfate; and the 250 mg capsule shell contains D&C Red #28 and FD&C Blue #1.

Amoxicillin for Oral Suspension USP

Each 5 mL of reconstituted suspension contains 125 mg or 250 mg of amoxicillin, USP as the trihydrate.

Inactive Ingredients: SUSPENSION: FD&C Red #40, mixed berry flavoring, silicon dioxide, sodium benzoate, sodium citrate, sucrose, and xanthan gum.

Amoxicillin Tablets USP (Chewable)

Each chewable tablet, for oral administration, contains 125 mg or 250 mg of amoxicillin, USP as the trihydrate.

Inactive Ingredients: CHEWABLE TABLETS: cherry flavor, lactose anhydrous, magnesium stearate, mannitol, microcrystalline cellulose, sodium citrate, and sucrose.

12 CLINICAL PHARMACOLOGY

12.1 Mechanism of Action

Amoxicillin is an antibacterial drug [*see Microbiology (12.4)*].

12.3 Pharmacokinetics

Absorption

Amoxicillin is stable in the presence of gastric acid and is rapidly absorbed after oral administration. The effect of food on the absorption of amoxicillin from the tablets and suspension of amoxicillin has been partially investigated; 400 mg and 875 mg formulations have been studied only when administered

at the start of a light meal.

Orally administered doses of 250 mg and 500 mg amoxicillin capsules result in average peak blood levels 1 to 2 hours after administration in the range of 3.5 mcg/mL to 5 mcg/mL and 5.5 mcg/mL to 7.5 mcg/mL, respectively.

Mean amoxicillin pharmacokinetic parameters from an open, two-part, single-dose crossover bioequivalence study in 27 adults comparing 875 mg of amoxicillin with 875 mg of amoxicillin/clavulanate potassium showed that the 875 mg of amoxicillin tablet produces an $AUC_{0\text{ to } \infty}$ of 35.4 ± 8.1 mcg•hr/mL and a C_{max} of 13.8 ± 4.1 mcg/mL. Dosing was at the start of a light meal following an overnight fast.

Orally administered doses of amoxicillin suspension, 125 mg/5 mL and 250 mg/5 mL, result in average peak blood levels 1 to 2 hours after administration in the range of 1.5 mcg/mL to 3 mcg/mL and 3.5 mcg/mL to 5 mcg/mL, respectively.

Oral administration of single doses of 400 mg chewable tablets and 400 mg/5 mL suspension of amoxicillin to 24 adult volunteers yielded comparable pharmacokinetic data:

Table 3: Mean Pharmacokinetic Parameters of Amoxicillin (400 mg chewable tablets and 400 mg/5 mL suspension) in Healthy Adults

Dose ^a	$AUC_{0\text{ to } \infty}$ (mcg•hr/mL)	C_{max} (mcg/mL) ^b
Amoxicillin	Amoxicillin (\pm S.D.)	Amoxicillin (\pm S.D.)
400 mg (5 mL of suspension)	17.1 (3.1)	5.92 (1.62)
400 mg (1 chewable tablet)	17.9 (2.4)	5.18 (1.64)

a. Administered at the start of a light meal.

b. Mean values of 24 normal volunteers. Peak concentrations occurred approximately 1 hour after the dose.

Distribution

Amoxicillin diffuses readily into most body tissues and fluids, with the exception of brain and spinal fluid, except when meninges are inflamed. In blood serum, amoxicillin is approximately 20% protein-bound. Following a 1 gram dose and utilizing a special skin window technique to determine levels of the antibiotic, it was noted that therapeutic levels were found in the interstitial fluid.

Metabolism and Excretion

The half-life of amoxicillin is 61.3 minutes. Approximately 60% of an orally administered dose of amoxicillin is excreted in the urine within 6 to 8 hours. Detectable serum levels are observed up to 8 hours after an orally administered dose of amoxicillin. Since most of the amoxicillin is excreted unchanged in the urine, its excretion can be delayed by concurrent administration of probenecid [see *DRUG INTERACTIONS (7.1)*].

12.4 Microbiology

Mechanism of Action

Amoxicillin is similar to penicillin in its bactericidal action against susceptible bacteria during the stage of active multiplication. It acts through the inhibition of cell wall biosynthesis that leads to the death of the bacteria.

Mechanism of Resistance

Resistance to amoxicillin is mediated primarily through enzymes called beta-lactamases that cleave the

beta-lactam ring of amoxicillin, rendering it inactive.

Amoxicillin has been shown to be active against most isolates of the bacteria listed below, both *in vitro* and in clinical infections as described in the INDICATIONS AND USAGE section.

Gram-Positive Bacteria

Enterococcus faecalis

Staphylococcus spp.

Streptococcus pneumoniae

Streptococcus spp. (alpha and beta-hemolytic)

Gram-Negative Bacteria

Escherichia coli

Haemophilus influenzae

Helicobacter pylori

Proteus mirabilis

Susceptibility Testing

For specific information regarding susceptibility test interpretive criteria and associated test methods and quality control standards recognized by FDA for this drug, please see: <https://www.fda.gov/STIC>.

13 NONCLINICAL TOXICOLOGY

13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

Long-term studies in animals have not been performed to evaluate carcinogenic potential. Studies to detect mutagenic potential of amoxicillin alone have not been conducted; however, the following information is available from tests on a 4:1 mixture of amoxicillin and potassium clavulanate. Amoxicillin and potassium clavulanate was non-mutagenic in the Ames bacterial mutation assay, and the yeast gene conversion assay. Amoxicillin and potassium clavulanate was weakly positive in the mouse lymphoma assay, but the trend toward increased mutation frequencies in this assay occurred at doses that were also associated with decreased cell survival. Amoxicillin and potassium clavulanate was negative in the mouse micronucleus test and in the dominant lethal assay in mice. Potassium clavulanate alone was tested in the Ames bacterial mutation assay and in the mouse micronucleus test, and was negative in each of these assays. In a multi-generation reproduction study in rats, no impairment of fertility or other adverse reproductive effects were seen at doses up to 500 mg/kg (approximately 2 times the 3 g human dose based on body surface area).

14 CLINICAL STUDIES

14.1 *H. pylori* Eradication to Reduce the Risk of Duodenal Ulcer Recurrence

Randomized, double-blind clinical studies performed in the United States in patients with *H. pylori* and duodenal ulcer disease (defined as an active ulcer or history of an ulcer within 1 year) evaluated the efficacy of lansoprazole in combination with amoxicillin capsules and clarithromycin tablets as triple 14 day therapy, or in combination with amoxicillin capsules as dual 14 day therapy, for the eradication of *H. pylori*. Based on the results of these studies, the safety and efficacy of 2 different eradication regimens were established: **Triple Therapy:** Amoxicillin 1 gram twice daily/clarithromycin 500 mg twice daily/lansoprazole 30 mg twice daily (see Table 6). **Dual Therapy:** Amoxicillin 1 gram three times daily/lansoprazole 30 mg three times daily (see Table 7). All treatments were for 14 days. *H. pylori* eradication was defined as 2 negative tests (culture and histology) at 4 to 6 weeks following the

end of treatment. Triple therapy was shown to be more effective than all possible dual therapy combinations. Dual therapy was shown to be more effective than both monotherapies. Eradication of *H. pylori* has been shown to reduce the risk of duodenal ulcer recurrence.

Table 6. *H. pylori* Eradication Rates When Amoxicillin is Administered as Part of a Triple Therapy Regimen

Study	Triple Therapy	Triple Therapy
	Evaluable Analysis ^a [95% Confidence Interval] (Number of Patients)	Intent-to-Treat Analysis ^b [95% Confidence Interval] (Number of Patients)
Study 1	92 [80 to 97.7] (n = 48)	86 [73.3 to 93.5] (n = 55)
Study 2	86 [75.7 to 93.6] (n = 66)	83 [72 to 90.8] (n = 70)

^a. This analysis was based on evaluable patients with confirmed duodenal ulcer (active or within 1 year) and *H. pylori* infection at baseline defined as at least 2 of 3 positive endoscopic tests from CLOtest[®], histology, and/or culture. Patients were included in the analysis if they completed the study. Additionally, if patients dropped out of the study due to an adverse event related to the study drug, they were included in the analysis as failures of therapy.

^b. Patients were included in the analysis if they had documented *H. pylori* infection at baseline as defined above and had a confirmed duodenal ulcer (active or within 1 year). All dropouts were included as failures of therapy.

Table 7. *H. pylori* Eradication Rates When Amoxicillin is Administered as Part of a Dual Therapy Regimen

Study	Dual Therapy	Dual Therapy
	Evaluable Analysis ^a [95% Confidence Interval] (Number of Patients)	Intent-to-Treat Analysis ^b [95% Confidence Interval] (Number of Patients)
Study 1	77 [62.5 to 87.2] (n = 51)	70 [56.8 to 81.2] (n = 60)
Study 2	66 [51.9 to 77.5] (n = 58)	61 [48.5 to 72.9] (n = 67)

^a. This analysis was based on evaluable patients with confirmed duodenal ulcer (active or within 1 year) and *H. pylori* infection at baseline defined as at least 2 of 3 positive endoscopic tests from CLOtest[®], histology, and/or culture. Patients were included in the analysis if they completed the study. Additionally, if patients dropped out of the study due to an adverse event related to the study drug, they were included in the analysis as failures of therapy.

^b. Patients were included in the analysis if they had documented *H. pylori* infection at baseline as defined above and had a confirmed duodenal ulcer (active or within 1 year). All dropouts were included as failures of therapy.

15 REFERENCES

1. Swanson-Biearman B, Dean BS, Lopez G, Krenzelok EP. The effects of penicillin and cephalosporin ingestions in children less than six years of age. *Vet Hum Toxicol.* 1988; 30: 66-67.

16 HOW SUPPLIED/STORAGE AND HANDLING

Amoxicillin Capsules USP are supplied as follows:

250 mg: Opaque caramel cap and opaque buff body, hard gelatin capsule. Printed black “TEVA” on cap and “3107” on body portions of the capsule and contain 250 mg amoxicillin as the trihydrate. They are available in bottles of 100 (NDC 0093-3107-01) and 500 (NDC 0093-3107-05) capsules.

500 mg: Opaque buff cap and opaque buff body, hard gelatin capsules. Printed black “TEVA” on cap and “3109” on body portions of the capsules and contain 500 mg amoxicillin as the trihydrate. They are available in bottles of 50 (NDC 0093-3109-53) and 500 (NDC 0093-3109-05) capsules.

Amoxicillin for Oral Suspension USP is supplied as follows:

125 mg/5 mL: Each 5 mL of reconstituted mixed berry flavored suspension contains 125 mg amoxicillin as the trihydrate. It is available in bottles of 80 mL (NDC 0093-4150-79), and 150 mL (NDC 0093-4150-80).

250 mg/5 mL: Each 5 mL of reconstituted mixed berry flavored suspension contains 250 mg amoxicillin as the trihydrate. It is available in bottles of 80 mL (NDC 0093-4155-79), 100 mL (NDC 0093-4155-73), and 150 mL (NDC 0093-4155-80).

Amoxicillin Tablets USP (Chewable) are supplied as follows:

125 mg: White to off-white, capsule-shaped tablet, unscored, debossed 93 on one side and 2267 on the other side and contain 125 mg amoxicillin as the trihydrate. They are available in bottles of 100 tablets (NDC 0093-2267-01).

250 mg: White to off-white, capsule-shaped tablet, debossed 93 (partial bisect between 9 and 3) on one side and 2268 on the other side and contain 250 mg amoxicillin as the trihydrate. They are available in bottles of 100 tablets (NDC 0093-2268-01).

Store at 20° to 25°C (68° to 77°F) [See USP Controlled Room Temperature].

Dispense in a tight, light-resistant container as defined in the USP, with a child-resistant closure (as required).

KEEP THIS AND ALL MEDICATIONS OUT OF THE REACH OF CHILDREN.

17 PATIENT COUNSELING INFORMATION

Information for Patients

- Patients should be advised that amoxicillin may be taken every 8 hours or every 12 hours, depending on the dose prescribed.
- Patients should be counseled that antibacterial drugs, including amoxicillin, should only be used to treat bacterial infections. They do not treat viral infections (e.g., the common cold). When amoxicillin is prescribed to treat a bacterial infection, patients should be told that although it is common to feel better early in the course of therapy, the medication should be taken exactly as directed. Skipping doses or not completing the full course of therapy may: (1) decrease the effectiveness of the immediate treatment, and (2) increase the likelihood that bacteria will develop resistance and will not be treatable by amoxicillin or other antibacterial drugs in the future.

- Patients should be counseled that diarrhea is a common problem caused by antibiotics, and it usually ends when the antibiotic is discontinued. Sometimes after starting treatment with antibiotics, patients can develop watery and bloody stools (with or without stomach cramps and fever) even as late as 2 or more months after having taken their last dose of the antibiotic. If this occurs, patients should contact their physician as soon as possible.
- Patients should be aware that amoxicillin contains a penicillin class drug product that can cause allergic reactions in some individuals.

All brand names listed are the registered trademarks of their respective owners and are not trademarks of Teva Pharmaceuticals USA.

Manufactured In Canada By:

Teva Canada Limited

Toronto, Canada M1B 2K9

Manufactured For:

Teva Pharmaceuticals USA, Inc.

North Wales, PA 19454

Rev. Z 8/2018

Package/Label Display Panel

NDC 0093-3107-05

Amoxicillin Capsules USP 250 mg

Each capsule contains amoxicillin trihydrate equivalent to 250 mg amoxicillin, USP.

Usual Adult Dosage: 1 or 2 capsules every 8 hours. See accompanying literature.

Store at 20° to 25°C (68° to 77°F) [See USP Controlled Room Temperature].

Dispense in a tight, light-resistant container as defined in the USP, with a child-resistant closure (as required).

KEEP THIS AND ALL MEDICATIONS OUT OF THE REACH OF CHILDREN.

Manufactured In Canada By:
TEVA CANADA LIMITED
Toronto, Canada M1B 2K9

Manufactured For:
TEVA PHARMACEUTICALS USA, INC.
North Wales, PA 19454

361-32- 669866270 Rev 03 Rev. J 9/2015

LOT
EXP.

500 CAPSULES

TEVA

Amoxicillin Capsules USP 250 mg 500s Label Text

NDC 0093-3107-05

**Amoxicillin
Capsules USP
250 mg**

Rx only

500 CAPSULES

TEVA

Package/Label Display Panel

GTIN 00930933109055

NDC 0093-3109-05

**Amoxicillin
Capsules USP
500 mg**

Rx only

500 CAPSULES

TEVA

Each capsule contains amoxicillin trihydrate equivalent to 500 mg amoxicillin, USP.

Usual Adult Dosage: 1 capsule every 8 hours. See accompanying literature.

Store at 20° to 25°C (68° to 77°F) [See USP Controlled Room Temperature].

Dispense in a tight, light-resistant container as defined in the USP, with a child-resistant closure (as required).

KEEP THIS AND ALL MEDICATIONS OUT OF THE REACH OF CHILDREN.

Manufactured In Canada By:
TEVA CANADA LIMITED
Toronto, Canada M1B 2K9

Manufactured For:
TEVA PHARMACEUTICALS USA, INC.
North Wales, PA 19454

361-32- 669876270 Rev 03 Rev. J 9/2015

LOT
EXP.

3 N 0093-3109-05 5

Amoxicillin Capsules USP 500 mg 500s Label Text

NDC 0093-3109-05

**Amoxicillin
Capsules USP
500 mg**

Rx only

500 CAPSULES

TEVA

Package/Label Display Panel



Amoxicillin for Oral Suspension USP 125 mg per 5 mL 100 mL Label Text

NDC 0093-4150-79

**Amoxicillin
for Oral Suspension USP**
equivalent to
125 mg per 5 mL
amoxicillin when reconstituted
according to directions.

See accompanying literature.

WARNING: NOT FOR INJECTION

Rx only

80 mL (when mixed)

TEVA

Package/Label Display Panel

NDC 0093-4155-73

Amoxicillin for Oral Suspension USP

equivalent to
250 mg per 5 mL
amoxicillin when reconstituted
according to directions.

See accompanying literature.
WARNING: NOT FOR INJECTION

Rx only

100 mL (when mixed)

TEVA

GTIN 00300934155730

Amoxicillin trihydrate equivalent to 5 g
amoxicillin, USP.

Usual Dosage: Adults – 250 mg to
500 mg every eight hours, depending on
type and severity of infection.

Children – 20 mg to 40 mg/kg/day in divided
doses every eight hours, depending on type
and severity of infection.

Store dry powder at 20° to 25°C (68° to 77°F)
[See USP Controlled Room Temperature].

TO THE PHARMACIST: Prepare suspension
at time of dispensing. Add to the bottle a total
of 60 mL of water. For ease in preparation, tap
bottle to loosen powder, add the water in two
portions, shaking well after each addition. The
resulting suspension will contain amoxicillin
trihydrate equivalent to 250 mg amoxicillin,
USP in each 5 mL (teaspoonful).

IMPORTANT

When stored at room temperature or in
refrigerator discard unused portion of
reconstituted suspension after 14 days.

Date of reconstitution:.....
Shake well before using. Keep tightly closed.
KEEP THIS AND ALL MEDICATIONS OUT
OF THE REACH OF CHILDREN.

Manufactured In Canada By:
TEVA CANADA LIMITED
Toronto, Canada M1B 2K9

Manufactured For:
TEVA PHARMACEUTICALS USA, INC.
North Wales, PA 19454

N 0093-4155-73 0



361-32- 669656240A Rev 03 Rev. G 9/2015

Non Varnish/Coding Area

Amoxicillin for Oral Suspension USP 250 mg per 5 mL 100 mL Label Text

NDC 0093-4155-73

**Amoxicillin
for Oral Suspension USP**
equivalent to
250 mg per 5 mL

amoxicillin when reconstituted
according to directions.

See accompanying literature.

WARNING: NOT FOR INJECTION

Rx only

100 mL (when mixed)


TEVA

Package/Label Display Panel

NDC 0093-2267-01
**Amoxicillin
 Tablets USP
 (Chewable)
 125 mg**
 Rx only
 100 TABLETS
TEVA

GTIN 00300932267015
 Each chewable tablet contains 125 mg amoxicillin, USP as the trihydrate.
Usual Dosage: Adults: 250 to 500 mg every 8 hours.
Children: 20 to 40 mg/kg/day in divided doses every 8 hours, depending on age, weight and severity of infection.
Read accompanying literature before use.
 Store at 20° to 25°C (68° to 77°F) [See USP Controlled Room Temperature].
 Dispense in a tight, light-resistant container as defined in the USP, with a child-resistant closure (as required).
KEEP THIS AND ALL MEDICATIONS OUT OF THE REACH OF CHILDREN.
 Manufactured in Canada By: TEVA CANADA LIMITED
 Toronto, Canada M1B 2K9
 Manufactured For: TEVA PHARMACEUTICALS USA, INC.
 North Wales, PA 19454

361-32- 669676240A Rev 03 Rev. C 9/2015

N 3 0093-2267-01 5


LOT
 EXP.

Amoxicillin Tablets USP (Chewable) 125 mg 100s Label Text

NDC 0093-2267-01

**Amoxicillin
 Tablets USP
 (Chewable)
 125 mg**

Rx only

100 TABLETS


TEVA

Package/Label Display Panel

NDC 0093-2268-01
**Amoxicillin
 Tablets USP
 (Chewable)
 250 mg**
 Rx only
 100 TABLETS
TEVA

GTIN 00300932268012
 Each chewable tablet contains 250 mg amoxicillin, USP as the trihydrate.
Usual Dosage: Adults: 250 to 500 mg every 8 hours.
Children: 20 to 40 mg/kg/day in divided doses every 8 hours, depending on age, weight and severity of infection.
Read accompanying literature before use.
 Store at 20° to 25°C (68° to 77°F) [See USP Controlled Room Temperature].
 Dispense in a tight, light-resistant container as defined in the USP, with a child-resistant closure (as required).
KEEP THIS AND ALL MEDICATIONS OUT OF THE REACH OF CHILDREN.
 Manufactured in Canada By: TEVA CANADA LIMITED
 Toronto, Canada M1B 2K9
 Manufactured For: TEVA PHARMACEUTICALS USA, INC.
 North Wales, PA 19454

361-32- 669686240A Rev 03 Rev. C 9/2015

N 3 0093-2268-01 2


LOT
 EXP.

Amoxicillin Tablets USP (Chewable) 250 mg 500s Label Text

NDC 0093-2268-01

**Amoxicillin
Tablets USP
(Chewable)
250 mg**

Rx only

100 TABLETS

TEVA

AMOXICILLIN

amoxicillin capsule

Product Information

Product Type	HUMAN PRESCRIPTION DRUG	Item Code (Source)	NDC:0093-3107
Route of Administration	ORAL		

Active Ingredient/Active Moiety

Ingredient Name	Basis of Strength	Strength
AMOXICILLIN (UNII: 804826J2HU) (AMOXICILLIN ANHYDROUS - UNII:9EM05410Q9)	AMOXICILLIN ANHYDROUS	250 mg

Inactive Ingredients

Ingredient Name	Strength
MAGNESIUM STEARATE (UNII: 70097M6I30)	
TALC (UNII: 7SEV7J4R1U)	
FERROSO FERRIC OXIDE (UNII: XM0M87F357)	
D&C YELLOW NO. 10 (UNII: 35SW5USQ3G)	
FD&C BLUE NO. 1 (UNII: HBR47K3TBD)	
FD&C BLUE NO. 2 (UNII: L06K8R7DQK)	
FD&C RED NO. 40 (UNII: WZB9127XOA)	
GELATIN (UNII: 2G86QN327L)	
PROPYLENE GLYCOL (UNII: 6DC9Q167V3)	
SHELLAC (UNII: 46N107B71O)	
TITANIUM DIOXIDE (UNII: 15FIX9V2JP)	
D&C RED NO. 28 (UNII: 767IP0Y5NH)	

Product Characteristics

Color	BROWN (caramel) , BROWN (buff)	Score	no score
Shape	CAPSULE	Size	18mm
Flavor		Imprint Code	TEVA;3107
Contains			

Packaging

#	Item Code	Package Description	Marketing Start Date	Marketing End Date
1	NDC:0093-3107-01	100 in 1 BOTTLE; Type 0: Not a Combination Product	09/30/1990	
2	NDC:0093-3107-05	500 in 1 BOTTLE; Type 0: Not a Combination Product	09/30/1990	

Marketing Information

Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date
ANDA	ANDA061926	09/30/1990	

AMOXICILLIN

amoxicillin capsule

Product Information

Product Type	HUMAN PRESCRIPTION DRUG	Item Code (Source)	NDC:0093-3109
Route of Administration	ORAL		

Active Ingredient/Active Moiety

Ingredient Name	Basis of Strength	Strength
AMOXICILLIN (UNII: 804826J2HU) (AMOXICILLIN ANHYDROUS - UNII:9EM05410Q9)	AMOXICILLIN ANHYDROUS	500 mg

Inactive Ingredients

Ingredient Name	Strength
MAGNESIUM STEARATE (UNII: 70097M6I30)	
TALC (UNII: 7SEV7J4R1U)	
FERROSO FERRIC OXIDE (UNII: XM0M87F357)	
D&C YELLOW NO. 10 (UNII: 35SW5USQ3G)	
FD&C BLUE NO. 1 (UNII: HBR47K3TBD)	
FD&C BLUE NO. 2 (UNII: L06K8R7DQK)	
FD&C RED NO. 40 (UNII: WZB9127XOA)	
GELATIN (UNII: 2G86QN327L)	
PROPYLENE GLYCOL (UNII: 6DC9Q167V3)	
SHELLAC (UNII: 46N107B71O)	
TITANIUM DIOXIDE (UNII: 15FIX9V2JP)	
METHYL PARABEN (UNII: A2I8C7HI9T)	
POTASSIUM HYDROXIDE (UNII: WZH3C48M4T)	
PROPYL PARABEN (UNII: Z8IX2SC1OH)	
SODIUM LAURYL SULFATE (UNII: 368GB5141J)	

Product Characteristics

Color	BROWN (buff)	Score	no score
Shape	CAPSULE	Size	22mm
Flavor		Imprint Code	TEVA;3109

Contains**Packaging**

#	Item Code	Package Description	Marketing Start Date	Marketing End Date
1	NDC:0093-3109-05	500 in 1 BOTTLE; Type 0: Not a Combination Product	09/30/1990	
2	NDC:0093-3109-53	50 in 1 BOTTLE; Type 0: Not a Combination Product	09/30/1990	

Marketing Information

Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date
ANDA	ANDA061926	09/30/1990	

AMOXICILLIN

amoxicillin powder, for suspension

Product Information

Product Type	HUMAN PRESCRIPTION DRUG	Item Code (Source)	NDC:0093-4150
Route of Administration	ORAL		

Active Ingredient/Active Moiety

Ingredient Name	Basis of Strength	Strength
AMO XICILLIN (UNII: 804826J2HU) (AMOXICILLIN ANHYDROUS - UNII:9EM05410Q9)	AMO XICILLIN ANHYDROUS	125 mg in 5 mL

Inactive Ingredients

Ingredient Name	Strength
FD&C RED NO. 40 (UNII: WZB9127XOA)	
SILICON DIO XIDE (UNII: ETJ7Z6XBU4)	
SODIUM BENZOATE (UNII: OJ245FE5EU)	
SODIUM CITRATE (UNII: 1Q73Q2JULR)	
SUCROSE (UNII: C151H8M554)	
XANTHAN GUM (UNII: TTV12P4NEE)	

Product Characteristics

Color	PINK	Score	
Shape		Size	
Flavor	BERRY	Imprint Code	
Contains			

Packaging

#	Item Code	Package Description	Marketing Start Date	Marketing End Date
1	NDC:0093-4150-79	80 mL in 1 BOTTLE; Type 0: Not a Combination Product	09/30/1990	09/30/2021

Marketing Information

Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date
ANDA	ANDA061931	09/30/1990	09/30/2021

AMOXICILLIN

amoxicillin powder, for suspension

Product Information

Product Type	HUMAN PRESCRIPTION DRUG	Item Code (Source)	NDC:0093-4155
Route of Administration	ORAL		

Active Ingredient/Active Moiety

Ingredient Name	Basis of Strength	Strength
AMOXICILLIN (UNII: 804826J2HU) (AMOXICILLIN ANHYDROUS - UNII:9EM05410Q9)	AMOXICILLIN ANHYDROUS	250 mg in 5 mL

Inactive Ingredients

Ingredient Name	Strength
FD&C RED NO. 40 (UNII: WZB9127XOA)	
SILICON DIOXIDE (UNII: ETJ7Z6XBU4)	
SODIUM BENZOATE (UNII: OJ245FE5EU)	
SODIUM CITRATE (UNII: 1Q73Q2JULR)	
SUCROSE (UNII: C151H8M554)	
XANTHAN GUM (UNII: TTV12P4NEE)	

Product Characteristics

Color	PINK	Score	
Shape		Size	
Flavor	BERRY	Imprint Code	
Contains			

Packaging

#	Item Code	Package Description	Marketing Start Date	Marketing End Date
1	NDC:0093-4155-73	100 mL in 1 BOTTLE; Type 0: Not a Combination Product	09/30/1990	
2	NDC:0093-4155-79	80 mL in 1 BOTTLE; Type 0: Not a Combination Product	09/30/1990	
3	NDC:0093-4155-80	150 mL in 1 BOTTLE; Type 0: Not a Combination Product	09/30/1990	

Marketing Information

Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date
ANDA	ANDA061931	09/30/1990	

AMOXICILLIN

amoxicillin tablet, chewable

Product Information

Product Type	HUMAN PRESCRIPTION DRUG	Item Code (Source)	NDC:0093-2267
Route of Administration	ORAL		

Active Ingredient/Active Moiety

Ingredient Name	Basis of Strength	Strength
AMOXICILLIN (UNII: 804826J2HU) (AMOXICILLIN ANHYDROUS - UNII:9EM05410Q9)	AMOXICILLIN ANHYDROUS	125 mg

Inactive Ingredients

Ingredient Name	Strength
ANHYDROUS LACTOSE (UNII: 3SY5LH9PMK)	
MAGNESIUM STEARATE (UNII: 70097M6I30)	
MANNITOL (UNII: 3OWL53L36A)	
CELLULOSE, MICROCRYSTALLINE (UNII: OP1R32D61U)	
SODIUM CITRATE (UNII: 1Q73Q2JULR)	
SUCROSE (UNII: C151H8M554)	

Product Characteristics

Color	WHITE (white to off-white)	Score	no score
Shape	OVAL (capsule-shaped)	Size	15mm
Flavor	CHERRY	Imprint Code	93;2267
Contains			

Packaging

#	Item Code	Package Description	Marketing Start Date	Marketing End Date
1	NDC:0093-2267-01	100 in 1 BOTTLE; Type 0: Not a Combination Product	10/01/1995	

Marketing Information

Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date
ANDA	ANDA064013	10/01/1995	

AMOXICILLIN

amoxicillin tablet, chewable

Product Information

Product Type	HUMAN PRESCRIPTION DRUG	Item Code (Source)	NDC:0093-2268
Route of Administration	ORAL		

Active Ingredient/Active Moiety

Ingredient Name	Basis of Strength	Strength
AMOXICILLIN (UNII: 804826J2HU) (AMOXICILLIN ANHYDROUS - UNII:9EM05410Q9)	AMOXICILLIN ANHYDROUS	250 mg

Inactive Ingredients

Ingredient Name	Strength
ANHYDROUS LACTOSE (UNII: 3SY5LH9PMK)	
MAGNESIUM STEARATE (UNII: 70097M6I30)	
MANNITOL (UNII: 3OWL53L36A)	
CELLULOSE, MICROCRYSTALLINE (UNII: OP1R32D61U)	
SODIUM CITRATE (UNII: 1Q73Q2JULR)	
SUCROSE (UNII: C151H8M554)	

Product Characteristics

Color	WHITE (white to off-white)	Score	2 pieces
Shape	OVAL (capsule-shaped)	Size	19mm
Flavor	CHERRY	Imprint Code	9;3;2268
Contains			

Packaging

#	Item Code	Package Description	Marketing Start Date	Marketing End Date
1	NDC:0093-2268-01	100 in 1 BOTTLE; Type 0: Not a Combination Product	01/01/1993	

Marketing Information

Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date
ANDA	ANDA064013	01/01/1993	

Labeler - Teva Pharmaceuticals USA, Inc. (001627975)